Jiangsu Yahong Meditech Co. Ltd.
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis … Read more
Jiangsu Yahong Meditech Co. Ltd. (688176) - Total Assets
Latest total assets as of September 2025: CN¥2.15 Billion CNY
Based on the latest financial reports, Jiangsu Yahong Meditech Co. Ltd. (688176) holds total assets worth CN¥2.15 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jiangsu Yahong Meditech Co. Ltd. - Total Assets Trend (2018–2024)
This chart illustrates how Jiangsu Yahong Meditech Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jiangsu Yahong Meditech Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Yahong Meditech Co. Ltd.'s total assets of CN¥2.15 Billion consist of 68.9% current assets and 31.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 28.3% |
| Accounts Receivable | CN¥71.53 Million | 3.2% |
| Inventory | CN¥5.84 Million | 0.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥53.98 Million | 2.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Jiangsu Yahong Meditech Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Yahong Meditech Co. Ltd.'s current assets represent 68.9% of total assets in 2024, a decrease from 82.1% in 2018.
- Cash Position: Cash and equivalents constituted 28.3% of total assets in 2024, down from 43.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 3.2% of total assets.
Jiangsu Yahong Meditech Co. Ltd. Competitors by Total Assets
Key competitors of Jiangsu Yahong Meditech Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jiangsu Yahong Meditech Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jiangsu Yahong Meditech Co. Ltd. generates 0.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jiangsu Yahong Meditech Co. Ltd. is currently not profitable relative to its asset base.
Jiangsu Yahong Meditech Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.99 | 8.99 | 20.88 |
| Quick Ratio | 4.96 | 8.97 | 20.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.46 Billion | CN¥ 1.42 Billion | CN¥ 777.63 Million |
Jiangsu Yahong Meditech Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Jiangsu Yahong Meditech Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -15.5% |
| Total Assets | CN¥2.22 Billion |
| Market Capitalization | $769.25 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Yahong Meditech Co. Ltd.'s assets below their book value (0.35 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jiangsu Yahong Meditech Co. Ltd.'s assets decreased by 15.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jiangsu Yahong Meditech Co. Ltd. (2018–2024)
The table below shows the annual total assets of Jiangsu Yahong Meditech Co. Ltd. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.22 Billion | -15.55% |
| 2023-12-31 | CN¥2.63 Billion | -8.41% |
| 2022-12-31 | CN¥2.87 Billion | -7.26% |
| 2021-12-31 | CN¥3.10 Billion | +264.82% |
| 2020-12-31 | CN¥849.43 Million | +1067.71% |
| 2019-12-31 | CN¥72.74 Million | +10.09% |
| 2018-12-31 | CN¥66.08 Million | -- |